Journal of Clinical Lipidology
Volume 4, Issue 4 , Pages 288-292 , July 2010

No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins

  • Anders Hovland, MD

      Affiliations

    • Coronary Care Unit, Department of Internal Medicine, Nordland Hospital, Prinsens gate, N-8092 Bodø, Norway
    • Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway
    • Corresponding Author InformationCorresponding author.
    • ,
  • Inger Aagnes, MD

      Affiliations

    • Coronary Care Unit, Department of Internal Medicine, Nordland Hospital, Prinsens gate, N-8092 Bodø, Norway
    • ,
  • Ole-Lars Brekke, MD, PhD

      Affiliations

    • Department of Laboratory Medicine, Nordland Hospital, Bodø, Norway
    • Institute of Medical Biology, University of Tromsø, Tromsø, Norway
    • ,
  • John Helge Flage, RN

      Affiliations

    • Coronary Care Unit, Department of Internal Medicine, Nordland Hospital, Prinsens gate, N-8092 Bodø, Norway
    • ,
  • Knut Tore Lappegård, MD, PhD

      Affiliations

    • Coronary Care Unit, Department of Internal Medicine, Nordland Hospital, Prinsens gate, N-8092 Bodø, Norway
    • Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway

Received 30 January 2010 ,Accepted 1 February 2010.

References 

  1. Scientific Steering Committee om behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis. 1999;142:105–112
  2. Neil HA, Huxley RR, Hawkins MM, Durrington PN, Betteridge DJ, Humphries SE. Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis. 2003;170:73–78
  3. National Institute for Health and Clinical Excellence. Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: the Identification and Management of Adults And Children With Familial Hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008;
  4. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands. Atherosclerosis. 2010;209:189–194
  5. Cheng HM, Ye ZX, Chiou KR, Lin SJ, Charng MJ. Vascular stiffness in familial hypercholesterolaemia is associated with C-reactive protein and cholesterol burden. Eur J Clin Invest. 2007;37:197–206
  6. Kastelein JJ, Wiegman A, de Groot E. Surrogate markers of atherosclerosis: impact of statins. Atheroscler Suppl. 2003;4:31–36
  7. Junyent M, Gilabert R, Jarauta E, et al. Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. 2010;208:437–441
  8. Truschel E, Jarczok MN, Fischer JE, Terris DD. High-throughput ambulatory assessment of digital reactive hyperemia: concurrent validity with known cardiovascular risk factors and potential confounding. Prev Med. 2009;49:468–472
  9. Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44:2137–2141
  10. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1695
  11. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009;54:669–677
  12. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol. 2007;14:55–61
  13. Healy B. Endothelial cell dysfunction: an emerging endocrinopathy linked to coronary disease. J Am Coll Cardiol. 1990;16:357–358
  14. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008;117:2467–2474
  15. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160:407–420
  16. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111–1115
  17. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  18. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481–487
  19. Vita JA, Yeung AC, Winniford M, et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation. 2000;102:846–851
  20. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488–493
  21. Mayer J, Eller T, Brauer P, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 1992;64:196–201
  22. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:247–251
  23. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  24. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  25. Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003;146:168–174
  26. Patvardhan EA, Heffernan KS, Ruan JM, Soffler MI, Karas RH, Kuvin JT. Assessment of vascular endothelial function with peripheral arterial tonometry: information at your fingertips?. Cardiol Rev. 2010;18:20–28
  27. Hamburg NM, Benjamin EJ. Assessment of endothelial function using digital pulse amplitude tonometry. Trends Cardiovasc Med. 2009;19:6–11
  28. Haller MJ, Stein J, Shuster J, et al. Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. Pediatr Diabetes. 2007;8:193–198
  29. Mahmud FH, Van US, Kanji N, Thiessen-Philbrook H, Clarson CL. Impaired endothelial function in adolescents with type 1 diabetes mellitus. J Pediatr. 2008;152:557–562
  30. Haller MJ, Stein JM, Shuster JJ, et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2009;22:65–68
  31. Charakida M, Tousoulis D, Skoumas I, et al. Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia. Atherosclerosis. 2009;204:532–537
  32. Guardamagna O, Abello F, Saracco P, Baracco V, Rolfo E, Pirro M. Endothelial activation, inflammation and premature atherosclerosis in children with familial dyslipidemia. Atherosclerosis. 2009;207:471–475
  33. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011
  34. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690–695
  35. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–2528

PII: S1933-2874(10)00222-9

doi: 10.1016/j.jacl.2010.02.011

Journal of Clinical Lipidology
Volume 4, Issue 4 , Pages 288-292 , July 2010

Article Tools

* Image Usage & Resolution